Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <i>BRAF</i> -Mutant Metastatic Non–Small Cell Lung Cancer

Abstract

ctDNA sequencing is clinically relevant for the detection of <i>BRAF</i>-activating mutations and the identification of alterations potentially related to resistance to BRAF-TT in <i>BRAF</i>-mutant NSCLC.